You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 3, 2025

AKTEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Akten, and when can generic versions of Akten launch?

Akten is a drug marketed by Thea Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in AKTEN is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Akten

A generic version of AKTEN was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18th, 1982.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AKTEN?
  • What are the global sales for AKTEN?
  • What is Average Wholesale Price for AKTEN?
Summary for AKTEN
International Patents:2
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 141
Drug Prices: Drug price information for AKTEN
What excipients (inactive ingredients) are in AKTEN?AKTEN excipients list
DailyMed Link:AKTEN at DailyMed
Drug patent expirations by year for AKTEN
Drug Prices for AKTEN

See drug prices for AKTEN

Pharmacology for AKTEN

US Patents and Regulatory Information for AKTEN

AKTEN is protected by one US patents.

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Thea Pharma AKTEN lidocaine hydrochloride GEL;OPHTHALMIC 022221-001 Oct 7, 2008 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 1 of 1 entries

International Patents for AKTEN

See the table below for patents covering AKTEN around the world.

CountryPatent NumberTitleEstimated Expiration
European Patent Office 2043601 FORMULATION DE GEL AQUEUX ET PROCÉDÉ POUR INDUIRE UNE ANESTHÉSIE TOPIQUE (AQUEOUS GEL FORMULATION AND METHOD FOR INDUCING TOPICAL ANESTHESIA) ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2008014036 ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 2 of 2 entries

AKTEN Market Analysis and Financial Projection

Market Dynamics and Financial Trajectory of Anesthesia Drugs: A Comprehensive Overview

Introduction to Anesthesia Drugs Market

The anesthesia drugs market is a vital segment of the pharmaceutical industry, driven by the increasing demand for surgical procedures and the development of new anesthetic medications. Here, we will delve into the market dynamics, financial trajectory, and key factors influencing the growth of this market.

Global Anesthesia Drugs Market Size and Forecast

The global anesthesia drugs market is projected to reach USD 7.26 billion in 2024 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.40% to reach USD 8.57 billion by 2029[1][4].

Impact of COVID-19 on the Market

The COVID-19 pandemic had a significant impact on the anesthesia drugs market. In 2020, the demand for anesthesia drugs decreased due to the postponement or cancellation of elective surgeries. According to a study published in the British Journal of Surgery, around 28.4 million elective surgeries worldwide were estimated to be canceled or postponed during the peak disruption period[1].

Recovery and Growth Post-Pandemic

As healthcare activities resumed, the demand for anesthesia drugs rebounded. The completion of postponed surgeries and the increasing number of emergency surgeries have contributed to the market's recovery. For instance, in England and Wales, the total number of surgical procedures carried out in 2020 was 3,102,674, indicating a robust demand for anesthesia drugs[1].

Product Launches and Innovations

The market is also driven by the launch of new and innovative anesthesia drugs. For example, in February 2021, PainPass introduced the first Cannabidiol (CBD)/lidocaine product line for treating chronic pain and numbing muscles externally. Hikma Pharmaceuticals launched Bupivacaine HCl Injection in December 2021, and PAION AG received approval for Byfavo (remimazolam besylate) in June 2021 for procedural sedation[1][4].

Regional Market Analysis

North America: The Largest Market

North America, particularly the United States, dominates the anesthesia drugs market. The region faced significant shortages of critical anesthesia drugs during the COVID-19 pandemic, including midazolam, dexmedetomidine, propofol, and neuromuscular blocking agents. To address these shortages, companies like Hikma Pharmaceuticals have increased their production of anesthesia drugs[1][4].

Asia Pacific: The Fastest Growing Region

The Asia Pacific region is expected to grow at the highest CAGR over the forecast period. This growth is driven by increasing healthcare expenditure, a rising number of surgical procedures, and the expansion of healthcare infrastructure in the region[1].

Market Segmentation

The anesthesia drugs market is segmented by route of administration and end-user.

Route of Administration

  • Intravenous: This segment includes drugs like propofol, benzodiazepines, ketamine, and methohexital sodium. It is the largest and fastest-growing segment due to its widespread use in various surgical procedures[4].
  • Inhalational: This segment includes drugs like sevoflurane, desflurane, isoflurane, and nitrous oxide[4].

End User

  • Hospitals: Hospitals are the primary end-users of anesthesia drugs due to the high volume of surgical procedures performed in these settings.
  • Ambulatory Surgery Centers: These centers are also significant users, especially for outpatient procedures[4].

Key Players in the Market

The market is highly competitive, with several major players dominating the landscape. Key companies include:

  • Baxter International Inc.
  • Aspen Pharmacare Holdings Limited
  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • Pfizer Inc.[1]

Financial Trajectory

The financial trajectory of the anesthesia drugs market is positive, driven by increasing demand and innovative product launches. Here are some key financial highlights:

  • Market Size in 2024: USD 7.26 billion[1][4].
  • Projected Market Size in 2029: USD 8.57 billion[1].
  • CAGR (2024-2029): 3.40%[1].

Challenges and Opportunities

Challenges

  • Regulatory Hurdles: The approval process for new anesthesia drugs can be lengthy and stringent, posing a challenge for market growth.
  • Competition: The market is highly competitive, with several established players, making it challenging for new entrants to gain market share.

Opportunities

  • Innovative Products: The development and approval of new and innovative anesthesia drugs offer significant revenue-generating opportunities.
  • Growing Demand: The increasing number of surgical procedures globally presents a substantial opportunity for market growth.

Illustrative Statistics

  • Global Market Size in 2019: USD 5.4 billion[4].
  • Projected Global Market Size in 2031: USD 7.7 billion[4].
  • Number of Elective Surgeries Postponed/Canceled in 2020: Approximately 28.4 million[1].

Expert Insights

"Despite the challenges posed by the COVID-19 pandemic, the anesthesia drugs market has shown resilience and is expected to grow steadily over the forecast period. The launch of new products and the increasing demand for surgical procedures are key drivers of this growth," said an industry expert.

Key Takeaways

  • The global anesthesia drugs market is expected to reach USD 8.57 billion by 2029.
  • North America dominates the market, while the Asia Pacific region is the fastest growing.
  • The market is driven by the increasing number of surgical procedures and the launch of innovative products.
  • Key players include Baxter International Inc., Aspen Pharmacare Holdings Limited, and B. Braun Melsungen AG.
  • The market faces challenges such as regulatory hurdles and competition but offers opportunities through innovative products and growing demand.

FAQs

1. What is the current size of the global anesthesia drugs market?

The global anesthesia drugs market size is expected to reach USD 7.26 billion in 2024[1].

2. Which region is the fastest growing in the anesthesia drugs market?

The Asia Pacific region is estimated to grow at the highest CAGR over the forecast period[1].

3. Who are the major players in the global anesthesia drugs market?

Major players include Baxter International Inc., Aspen Pharmacare Holdings Limited, B. Braun Melsungen AG, Fresenius SE & Co. KGaA, and Pfizer Inc.[1].

4. What are the key drivers of the anesthesia drugs market?

The market is driven by the increasing number of surgical procedures, the launch of innovative products, and the recovery from the impact of the COVID-19 pandemic[1][4].

5. What is the projected CAGR of the global anesthesia drugs market from 2024 to 2029?

The market is expected to grow at a CAGR of 3.40% from 2024 to 2029[1].

Cited Sources:

  1. Mordor Intelligence: Global Anesthesia Drugs Market Report | Industry Analysis, Size & Forecast.
  2. Eagle Pharmaceuticals: Eagle Pharmaceuticals Provides Business Update and Reiterates Guidance.
  3. PubMed: The economics of follow-on drug research and development.
  4. SkyQuest: General Anesthesia Drugs Market Size, Share, Growth Analysis, By Route Of Administration, By End User and Region.
  5. FDA: Drug Approval Package: Akten NDA #022221.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.